147 related articles for article (PubMed ID: 1835644)
1. Clinical use of aromatase inhibitors in human breast carcinoma.
Santen RJ
J Steroid Biochem Mol Biol; 1991; 40(1-3):247-53. PubMed ID: 1835644
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in development of aromatase inhibitors.
Santen RJ
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1029-35. PubMed ID: 2149503
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of CGS 16949A. A new aromatase inhibitor.
Lipton A; Harvey HA; Demers LM; Hanagan JR; Mulagha MT; Kochak GM; Fitzsimmons S; Sanders SI; Santen RJ
Cancer; 1990 Mar; 65(6):1279-85. PubMed ID: 2137721
[TBL] [Abstract][Full Text] [Related]
4. Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.
Pérez N; Borja J
J Int Med Res; 1992 Aug; 20(4):303-12. PubMed ID: 1387368
[TBL] [Abstract][Full Text] [Related]
5. Potency and specificity of CGS-16949A as an aromatase inhibitor.
Santen RJ; Langecker P; Santner SJ; Sikka S; Rajfer J; Swerdloff R
Endocr Res; 1990; 16(1):77-91. PubMed ID: 2139412
[TBL] [Abstract][Full Text] [Related]
6. Clinical use of aromatase inhibitors in the treatment of breast cancers.
Manni A
J Cell Biochem Suppl; 1993; 17G():242-6. PubMed ID: 8007705
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of aromatase with CGS 16949A in postmenopausal women.
Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
[TBL] [Abstract][Full Text] [Related]
8. Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitor.
Santen RJ; Demers LM; Lynch J; Harvey H; Lipton A; Mulagha M; Hanagan J; Garber JE; Henderson IC; Navari RM
J Clin Endocrinol Metab; 1991 Jul; 73(1):99-106. PubMed ID: 1646219
[TBL] [Abstract][Full Text] [Related]
9. Aminoglutethimide and ketoconazole: historical perspectives and future prospects.
Shaw MA; Nicholls PJ; Smith HJ
J Steroid Biochem; 1988 Jul; 31(1):137-46. PubMed ID: 2969435
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.
Steele RE; Mellor LB; Sawyer WK; Wasvary JM; Browne LJ
Steroids; 1987; 50(1-3):147-61. PubMed ID: 2973160
[TBL] [Abstract][Full Text] [Related]
11. The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro.
Lamberts SW; Bruining HA; Marzouk H; Zuiderwijk J; Uitterlinden P; Blijd JJ; Hackeng WH; De Jong FH
J Clin Endocrinol Metab; 1989 Oct; 69(4):896-901. PubMed ID: 2550511
[TBL] [Abstract][Full Text] [Related]
12. Fadrozole hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the treatment of estrogen-dependent disease.
Browne LJ; Gude C; Rodriguez H; Steele RE; Bhatnager A
J Med Chem; 1991 Feb; 34(2):725-36. PubMed ID: 1825337
[TBL] [Abstract][Full Text] [Related]
13. Effect of aromatase inhibitors on estrogen 2-hydroxylase in rat liver.
Purba HS; King EJ; Richert P; Bhatnagar AS
J Steroid Biochem Mol Biol; 1994 Feb; 48(2-3):215-9. PubMed ID: 8142297
[TBL] [Abstract][Full Text] [Related]
14. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo.
Schieweck K; Bhatnagar AS; Matter A
Cancer Res; 1988 Feb; 48(4):834-8. PubMed ID: 2962734
[TBL] [Abstract][Full Text] [Related]
15. Novel aromatase inhibitors.
Bhatnagar AS; Häusler A; Schieweck K; Browne LJ; Bowman R; Steele RE
J Steroid Biochem Mol Biol; 1990 Nov; 37(3):363-7. PubMed ID: 2147860
[TBL] [Abstract][Full Text] [Related]
16. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A.
Stein RC; Dowsett M; Davenport J; Hedley A; Ford HT; Gazet JC; Coombes RC
Cancer Res; 1990 Mar; 50(5):1381-4. PubMed ID: 2137367
[TBL] [Abstract][Full Text] [Related]
17. Aromatase inhibitors--mechanisms for non-steroidal inhibitors.
Vanden Bossche HV; Moereels H; Koymans LM
Breast Cancer Res Treat; 1994; 30(1):43-55. PubMed ID: 7949204
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women.
Santen RJ; Boucher AE; Santner SJ; Henderson IC; Harvey H; Lipton A
J Lab Clin Med; 1987 Mar; 109(3):278-89. PubMed ID: 3546561
[TBL] [Abstract][Full Text] [Related]
19. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
Santen RJ
Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
[TBL] [Abstract][Full Text] [Related]
20. Plasma estrone and estrone sulphate in breast cancer patients treated with the aromatase inhibitor CGS 16949A.
Klepp R; Lønning PE; Kvinnsland S
Acta Oncol; 1990; 29(4):469-71. PubMed ID: 2143909
[No Abstract] [Full Text] [Related]
[Next] [New Search]
